poisar

Stocks · News reference

PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $397.424M Est

Benzinga Newsdesk

PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $397.424 million estimate.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PRCT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Kaplan Fox & Kilsheimer Llp

    Kaplan Fox Reminds Investors of a Securities Class Action Against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) – Deadline is September 22, 2026

    A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly using undisclosed discount programs that artificially inflated handpiece unit sales and revenues during the Class Period (February 28, 2024 to February 25, 2026). The complaint claims the company misrepresented that the differential between handpiece sales and procedures remained consistent, when in fact their sales tactics pulled forward demand artificially. The deadline to serve as lead plaintiff is September 22, 2026.

    PRCT
  2. Brendan Coffey

    Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors?

    Procept BioRobotics CEO Larry Wood purchased 23,900 shares (~$498,000) through a trust on August 7, 2026, expanding his beneficial stake to 338,103 shares. The purchase occurred as the stock declined 48% over the past year, but comes after the company reported 19% Q2 sales growth and Wood's reorganization efforts. Insider purchases are typically viewed as bullish signals, suggesting management confidence in the company's turnaround prospects despite ongoing net losses of $109.8 million on $337.3 million in trailing revenue.

    PRCT
  3. Kaplan Fox & Kilsheimer Llp

    Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors with Significant Losses to Contact the Firm Before September 22, 2026

    Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly using undisclosed discount programs that artificially inflated handpiece unit sales and revenues during the Class Period (February 28, 2024 - February 25, 2026). The firm is also pursuing cases against Hub Group, Inc. and investigating potential securities violations at Alignment Healthcare, Inc. Investors with losses are encouraged to contact the firm before respective deadlines.

    PRCTHUBGALHC